Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism
- Conditions
- Primary or Secondary HypogonadismConstitutional Delay in Growth and Puberty (CDGP)
- Registration Number
- NCT00193661
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
This study is to observe efficacy and safety after T-Gel 1% treatment in delayed puberty adolescents. Subjects who complete this trial may enter a 3 month extension study (UMD-01-090E).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- Not specified
- Primary or secondary hypogonadism or constitutional delay in growth and puberty (CDGP)
- Skin intolerance to alcohol or allergy to soy
- Generalized skin disease
- Contraindication to testosterone or androgen products
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (19)
Site 125
🇺🇸Philadelphia, Pennsylvania, United States
Site 126
🇺🇸Philadelphia, Pennsylvania, United States
Site 111
🇺🇸Kansas City, Missouri, United States
Site 130
🇺🇸Birmingham, Alabama, United States
Site 107
🇺🇸Los Angeles, California, United States
Site 113
🇺🇸Sacramento, California, United States
Site 114
🇺🇸Torrance, California, United States
Site 121
🇺🇸Gainesville, Florida, United States
Site 127
🇺🇸Jacksonville, Florida, United States
Site 117
🇺🇸Indianapolis, Indiana, United States
Site 123
🇺🇸New York, New York, United States
Site 131
🇺🇸Cincinnati, Ohio, United States
Site 109
🇺🇸Hershey, Pennsylvania, United States
Site 103
🇺🇸Portland, Oregon, United States
Site 124
🇺🇸Columbus, Ohio, United States
Site 205
🇺🇸Seattle, Washington, United States
Site 104
🇺🇸Memphis, Tennessee, United States
Site 129
🇺🇸Brooklyn, New York, United States
Site 128
🇺🇸Jacksonville, Florida, United States